Selected Grants
Symptom Management and Transitioning to Engagement with Post-treatment Care for Adolescent and Young Adult Cancer Survivors (AYA STEPS)
ResearchCo Investigator · Awarded by National Institutes of Health · 2024 - 2029POLARIS 2022-001: ADI-PEG 20 or Placebo Plus Gemcitabine and Docetaxel in Previously Treated Subjects with Leiomyosarcoma (ARGSARC): A Randomized, Double-Blind, Multi-Center Phase 3 Trial
Clinical TrialPrincipal Investigator · Awarded by Polaris Pharmaceuticals, Inc. · 2024 - 2029Defining Actionable Opportunities in Malignant Phyllodes via Genomic Profiling
ResearchCollaborator · Awarded by Food and Drug Administration · 2024 - 2027Brightline-4: A Phase III open-label, single-arm, multi-center study to assess the safety and efficacy of brigimadlin (BI 907828) treatment in patients with treatment-naive or pre-treated advanced dedifferentiated liposarcoma
Clinical TrialPrincipal Investigator · Awarded by Boehringer Ingelheim Pharmaceuticals, Inc. · 2024 - 2025ABSK021-301
Clinical TrialPrincipal Investigator · Awarded by Abbisko Therapeutics Co. LTD. · 2023 - 2025External Relationships
- Aadi
- Deciphera
- Ipsen
- Sorrento Therapeutics
This faculty member (or a member of their immediate family) has reported outside activities with the companies, institutions, or organizations listed above. This information is available to institutional leadership and, when appropriate, management plans are in place to address potential conflicts of interest.